Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis Inc., and Merck & Co., Inc.

Community Practice Connections™: Leveraging Evolving Data Sets to Inform Treatment Decision-Making in Advanced RCC: An Expert Tumor Board Discussion

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

This online activity is based on a live activity that was held adjunct to the 2019 annual oncology meeting in Chicago. It features video interviews with an esteemed faculty of internationally renowned experts in the treatment of patients with advanced renal cell carcinoma (RCC). Throughout this activity, these experts provide an in-depth review of the clinical impact of recent and emerging trial data for monotherapies and combination approaches in RCC. A series of tightly integrated case presentations illuminate RCC treatment decisions related to sequencing and switching based on patient and disease characteristics. Adverse events and their management are included in the commentary. Additionally, future directions in the field are addressed and considered in the context of how recent developments and highly anticipated trials may soon shape future care. Don’t miss this valuable opportunity to improve your practice!

Acknowledgement of Commercial Support

This activity is supported by educational grants from Exelixis Inc., and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with RCC are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the biologic rationale for use of targeted agents and immunotherapies, as single agents and in combination, to treat renal cell carcinoma (RCC)
  • Analyze practice-changing and emerging data from clinical trials of systemic therapies for use across multiple lines of therapy for advanced RCC
  • Integrate knowledge of the safety profile of systemic therapies and best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC
  • Consider the efficacy and safety of single-agent and combination systemic therapies, as well as patient and disease characteristics and patient preferences, as a part of shared decision-making for patients with metastatic RCC

Faculty, Staff, and Planners’ Disclosures


Robert A. Figlin
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant Research Support: Peloton, Exelixis, Calithera, Merck, Bristol-Myers Squibb; Consultant: Pfizer, Acceleron, Bristol-Myers Squibb, Eisai.

Laurence Albiges
Laurence Albiges, MD, PhD
Head, Genitourinary Tumor Unit
Department of Cancer Medicine
Gustave Roussy Institute
Villejuif Grand – Paris, France

Disclosures: Consultant: Pfizer, Novartis, Bristol-Myers Squibb, Ipsen, Roche, MSD, AstraZeneca.

Michael B. Atkins
Michael B. Atkins, MD
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
Professor of Oncology and Medicine (Hematology/Oncology)
Georgetown University School of Medicine
Washington, DC

Disclosures: Grant Research Support: Bristol-Myers Squibb; Consultant: Bristol-Myers Squibb, Merck, Eisai, Exelixis, Novartis, Genentech/Roche, Arrowhead, AVEO.

Sumanta K. Pal
Sumanta K. Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-Director, Kidney Cancer Program
City of Hope
Duarte, CA

Disclosures: Consultant: Genentech, AVEO, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, Bristol-Myers Squibb, Astellas.

Thomas Powles
Thomas Powles, MBBS, MRCP, MD
Clinical Professor of Genitourinary Oncology (HCC)
Experimental Cancer Medicine Centre
Barts Cancer Institute
Barts and The London School of Medicine and Dentistry
London, UK

Disclosures: Grant/Research Support: AstraZeneca, Roche; Consultant: Bristol-Myers Squibb, Ipsen, Exelixis, Roche, Merck, Pfizer, Novartis, AstraZeneca, Incyte, Seattle Genetics

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By